The past four years have been a roller-coaster ride for Moderna (NASDAQ: MRNA). The mRNA-focused vaccine maker rose to prominence following a successful attempt at developing a coronavirus vaccine.
However, the stock fell out of favor once sales of the company's only product on the market started moving in the wrong direction. Moderna's shares are down by 30% in the past year, but their total return over the past four years is 230%, and there remain good reasons to invest in the company.
Source Fool.com